



# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Non-Oral Contraceptives Fiscal Edit
<b>First Implementation Date:</b>	January 25, 2012
<b>Revised Date:</b>	May 11, 2023
<b>Prepared for:</b>	MO HealthNet
<b>Prepared by:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** To control expenditures by preventing duplication of non-oral contraceptive products

**Why Issue Selected:** Non-oral contraceptive agents include intrauterine devices (hormone-containing and copper-containing), transdermal patches, long-acting intramuscular injections, vaginal rings, and diaphragm devices. These options of birth control are largely safe and effective, with most products offering the patient the convenience of continuous contraception without requiring the use of a daily oral tablet. More than 10% of women who use birth control now chose a non-oral form. Because of the long-acting nature of these products, MO HealthNet has discovered the need to monitor utilization of these claims to prevent duplication of therapy from the various providers involved in the patient's care.

**Type of Criteria:**  Increased risk of ADE  Preferred Drug List  
 Appropriate Indications  Fiscal Edit

**Data Sources:**  Only Administrative Databases  Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: Non-Oral Contraceptives
- Age range: All appropriate MO HealthNet participants

## Approval Criteria

- Claim is within approved frequency limitations (see Appendix A)

## Denial Criteria

- Therapy will be denied if all approval criteria are not met

## Required Documentation

Laboratory Results:

Progress Notes:

MedWatch Form:

Other:

## Disposition of Edit

Denial: Exception code "0683" (Fiscal Edit)

Rule Type: CE

## Default Approval Period

1 year

## Appendix A

Brand Name	Generic Name	Frequency Limitation
Anovera Vaginal Ring	Segesterone Acetate/Ethinyl Estradiol	Once every 310 days
Caya Contoured Diaphragm	Diaphragm, Contoured 60mm – 85mm	Once every 310 days
Depo-Provera 104 SubQ	Medroxyprogesterone Acetate Syringe	Once every 71 days
Depo-Provera Syringe	Medroxyprogesterone Acetate Syringe	Once every 71 days
Depo-Provera Vial	Medroxyprogesterone Acetate Vial	Once every 71 days
Diaphragm(s)	Coil/Flat Spring/Arc-Spring	Once every 310 days
Femcap 22 mm Cervical Cap	Cervical Cap	Once every 310 days
Femcap 26 mm Cervical Cap	Cervical Cap	Once every 310 days
Femcap 30 mm Cervical Cap	Cervical Cap	Once every 310 days
Kyleena IUD System	Levonorgestrel	Once every 1,551 days
Liletta IUD System	Levonorgestrel	Once every 2,482 days
Mirena IUD System	Levonorgestrel	Once every 1,551 days
Nexplanon Implant	Etonogestrel	Once every 930 days
Nuvaring Vaginal Ring	Etonogestrel/Ethinyl Estradiol	Once every 24 days
Paragard T IUD	Copper Intra-Uterine Device	Once every 3,102 days
Phexxi 1.8-1-0.4% vaginal gel	Lactic acid/citric/potassium	120 grams (2 boxes) every 24 days
Skylla IUD System	Levonorgestrel	Once every 930 days
Twirla 120-30 mcg/day patch	Levonorgestrel/Ethinyl Estradiol	3 patches (1 box) every 24 days
Wide Seal Diaphragm 60 mm	Wide Seal 60 mm Diaphragm Vaginal	1 every 310 days
Wide Seal Diaphragm 65 mm	Wide Seal 65 mm Diaphragm Vaginal	1 every 310 days
Wide Seal Diaphragm 70 mm	Wide Seal 70 mm Diaphragm Vaginal	1 every 310 days
Wide Seal Diaphragm 75 mm	Wide Seal 75 mm Diaphragm Vaginal	1 every 310 days
Wide Seal Diaphragm 80 mm	Wide Seal 80 mm Diaphragm Vaginal	1 every 310 days
Wide Seal Diaphragm 85 mm	Wide Seal 85 mm Diaphragm Vaginal	1 every 310 days
Wide Seal Diaphragm 90 mm	Wide Seal 90 mm Diaphragm Vaginal	1 every 310 days
Wide Seal Diaphragm 95 mm	Wide Seal 95 mm Diaphragm Vaginal	1 every 310 days
Xulane Patch	Ethinyl Estradiol/Norelgestromin	3 patches (1 box) every 24 days

## References

- IPD Analytics. Women's Health: Contraception. Accessed November 17, 2021.